Board of Directors
Arnold Oronsky, Ph.D.
General Partner, InterWest Partners
Dr. Oronsky has been a General Partner at InterWest Partners since 1994. In addition to being a Senior Partner at InterWest, Dr. Oronsky also serves as a Senior Lecturer in the Department of Medicine at Johns Hopkins Medical School. Prior to joining InterWest, he was Vice President for Discovery Research for the Lederle Laboratories division of American Cyanamid Company where he directed research for new drugs.
Dr. Oronsky holds a Ph.D. in Immunology from Columbia University and an A.B. degree from New York University. He has published over 125 scientific articles, and serves as a Director on the Boards of several life science companies.
Peter Thompson, M.D.
Peter Thompson, M.D., is currently a Private Equity Partner with OrbiMed who brings over 25 years of industry experience. Peter co-founded and was CEO of Trubion Pharmaceuticals (NASDAQ: TRBN), co-founded Cleave BioSciences and Corvus Pharmaceuticals (NASDAQ:CRVS) and was previously an executive of Chiron Corporation and Becton Dickinson. Dr. Thompson also serves as a Director on several public and private company Boards, is an Ernst & Young Entrepreneur of the Year awardee and an Affiliate Professor of Neurosurgery at the University of Washington. He is the inventor on numerous patents, is a board-certified internist and oncologist and was on the staff at the National Cancer Institute following his internal medicine training at Yale University.
Arnold Levine, Ph.D.
Co-Founder & Member, Scientific Advisory Board
Arnold J. Levine is currently a Professor Emeritus at The Simons Center for Systems Biology at the Institute for Advanced Study in Princeton, and a joint Professor in the Pediatrics and Biochemistry Departments at the Cancer Institute of New Jersey. He received his B.A. in Biology from Harpur College, SUNY and his Ph.D. from the University of Pennsylvania.
He trained as a Postdoctoral Fellow at California Institute of Technology in the laboratory of Robert Sinsheimer. Dr. Levine is a widely acclaimed leader in cancer research. In 1979, Dr. Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. He established the Simons Center for Systems Biology at the Institute for Advanced Study, which concentrates on research at the interface of molecular biology and the physical sciences: on genetics and genomics, polymorphisms and molecular aspects of evolution, signal transduction pathways and networks, stress responses, and pharmacogenomics in cancer biology. Dr. Levine helped shape U.S. science priorities as chairman of an influential 1996 review panel on federal AIDS research funding. He also chaired the National Cancer Advisory Board, which advises the National Academy of Sciences and its Institute of Medicine on cancer policy. He was elected to the National Academy of Sciences in 1991 and to its Institute of Medicine in 1995. In April 2001, Levine received the first Albany Medical Center Prize in Medicine and Biomedical Research, the largest annual prize in science or medicine offered in the United States. In 1968 Dr. Levine joined Princeton University as an Assistant Professor, becoming a Professor of biochemistry in 1976. In 1979, he moved to the SUNY Stony Brook School of Medicine to Chair the Department of Microbiology. He returned to Princeton in 1984. Between 1984 and 1996, he presided over a major expansion of Princeton’s life sciences programs as Chairman of the Department of Molecular Biology. From 1998 to 2002, Dr. Levine was President of The Rockefeller University.
David H. Mack, Ph.D.
Co-Founder, President & CEO
Prior to co-founding PMV Pharma with biologists Arnold Levine and Thomas Shenk, Dr. Mack was a general partner at Alta Partners from 2002 to 2013. His first investment was Angiosyn (acquired by Pfizer in 2005) where he was a Director and CEO. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003).
From 1994 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. Dr. Mack was also a pivotal member of the Polymerase Chain Reaction (PCR) Invention Group at Cetus (now Novartis) in the mid 1980s. Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 26 issued US patents. Dr. Mack was an American Cancer Society Postdoctoral Fellow in microbiology and immunology at Stanford University School of Medicine. He received his Ph.D. from the University of Chicago, where he was a Howard Hughes Fellow in Molecular Genetics and Cell Biology, and a B.A. in Molecular Biology from the University of California, Berkeley.
Steve Winick, J.D.
Managing Partner, Topspin Fund
Steve is a Managing Director of Topspin Fund. He came to Topspin in 2004 from Honeywell, Intl., where he most recently served as CIO of its $2B Security Group.
He had been with Honeywell (and the Ademco division of Pittway Corp., before its acquisition by Honeywell in 2000) for over 21 years as CTO and CIO of the security business, as well as founder and president of its wireless communications services business.
Steve received a B.S. in Economics from the Wharton School of the University of Pennsylvania, and a B.S. in Electrical Engineering, also from Penn. He received his J.D. from Georgetown University Law Center and is both a member of the Bar of the State of New York, and a registered Patent Attorney.
Thilo Schroeder, Ph.D.
Thilo Schroeder, Ph.D. is a Partner at Nextech and has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality.
Thilo is a board member of Revolution Medicines, PMV Pharma, IDEAYA Biosciences (NASDAQ: IDYA), ImaginAb and is a board observer of Black Diamond Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC) and Peloton Therapeutics (acquired by Merck).
Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).